PATIENT WALLET CARD

Have This Card With You At All Times

Show It To Any Doctor That Sees You And When You Go To The Hospital

You should plan to stay within 2 hours of the location where you received your treatment for at least 4 weeks after getting Kymriah. Your healthcare provider will check to see if your treatment is working and help you with any side effects that occur.

Patient Information

Kymriah may cause side effects that are severe or life-threatening.

Call your oncologist or go to the emergency room if these signs appear.

SIGNS AND SYMPTOMS MAY INCLUDE:

- Difficulty breathing
- Fever (100.4°F/38°C or higher)
- Chills/shaking chills
- Confusion
- Severe nausea, vomiting, diarrhea
- Severe muscle or joint pain
- Very low blood pressure
- Dizziness/lightheadedness
- Headache

NOVARTIS
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080 © 2022 Novartis 05/22 206537

INFORMATION FOR THE HEALTHCARE PROVIDER

This patient has received Kymriah (CAR-T cell) therapy

Following Kymriah treatment, Cytokine Release Syndrome (CRS) can happen. It may include neurological toxicities.

Please contact his/her treating oncologist in the following situations:

- before giving steroids or cytotoxic medications
- if the patient has a serious infection
- before the patient undergoes an invasive procedure

fold *fold*

Date received Kymriah:_____

Oncologist Name (for Kymriah therapy): _____

Phone Number:_____

Kymriah is a CD19-directed genetically modified autologous T Cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse, adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma,* and adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. r/r FL is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in confirmatory trial(s).

*Limitation of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma

KYMRIAH®
(tisagenlecleucel) Suspension for IV infusion